Tags

Type your tag names separated by a space and hit enter

Inhaled hypertonic saline as a therapy for cystic fibrosis.
Curr Opin Pulm Med 2006; 12(6):445-52CO

Abstract

PURPOSE OF REVIEW

The beneficial effect of a short course of nebulized hypertonic saline on lung function for people with cystic fibrosis was first identified in 1996. At that time, competing hypotheses about the pathogenesis of cystic fibrosis lung disease predicted very different responses to long-term inhalation of hypertonic saline.

RECENT FINDINGS

Recent benchtop research supports the hypothesis that the liquid layer lining the airways is depleted in cystic fibrosis. In addition to osmotically restoring this liquid layer, hypertonic saline improves the rheological properties of the mucus and stimulates cough. The net result is accelerated mucus clearance that is short-lived for single doses but sustained with regular inhalation. Long-term use improves lung function mildly but has marked benefits with respect to exacerbations, quality of life and absenteeism, without promoting infection or inflammation.

SUMMARY

Hypertonic saline appears broadly applicable as an inexpensive therapy for most patients with cystic fibrosis.

Authors+Show Affiliations

Royal Prince Alfred Hospital, Australia.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17053496

Citation

Elkins, Mark R., and Peter T P. Bye. "Inhaled Hypertonic Saline as a Therapy for Cystic Fibrosis." Current Opinion in Pulmonary Medicine, vol. 12, no. 6, 2006, pp. 445-52.
Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med. 2006;12(6):445-52.
Elkins, M. R., & Bye, P. T. (2006). Inhaled hypertonic saline as a therapy for cystic fibrosis. Current Opinion in Pulmonary Medicine, 12(6), pp. 445-52.
Elkins MR, Bye PT. Inhaled Hypertonic Saline as a Therapy for Cystic Fibrosis. Curr Opin Pulm Med. 2006;12(6):445-52. PubMed PMID: 17053496.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhaled hypertonic saline as a therapy for cystic fibrosis. AU - Elkins,Mark R, AU - Bye,Peter T P, PY - 2006/10/21/pubmed PY - 2007/1/11/medline PY - 2006/10/21/entrez SP - 445 EP - 52 JF - Current opinion in pulmonary medicine JO - Curr Opin Pulm Med VL - 12 IS - 6 N2 - PURPOSE OF REVIEW: The beneficial effect of a short course of nebulized hypertonic saline on lung function for people with cystic fibrosis was first identified in 1996. At that time, competing hypotheses about the pathogenesis of cystic fibrosis lung disease predicted very different responses to long-term inhalation of hypertonic saline. RECENT FINDINGS: Recent benchtop research supports the hypothesis that the liquid layer lining the airways is depleted in cystic fibrosis. In addition to osmotically restoring this liquid layer, hypertonic saline improves the rheological properties of the mucus and stimulates cough. The net result is accelerated mucus clearance that is short-lived for single doses but sustained with regular inhalation. Long-term use improves lung function mildly but has marked benefits with respect to exacerbations, quality of life and absenteeism, without promoting infection or inflammation. SUMMARY: Hypertonic saline appears broadly applicable as an inexpensive therapy for most patients with cystic fibrosis. SN - 1070-5287 UR - https://www.unboundmedicine.com/medline/citation/17053496/Inhaled_hypertonic_saline_as_a_therapy_for_cystic_fibrosis_ L2 - http://Insights.ovid.com/pubmed?pmid=17053496 DB - PRIME DP - Unbound Medicine ER -